Evidence map›Paper›PMID 31247195›Full record

ArticleExperimental neurology2019

Docosahexaenoic acid decreased neuroinflammation in rat pups after controlled cortical impact.

Michelle E Schober, Daniela F Requena, T Charles Casper, Amy K Velhorst, Alyssa Lolofie, Katelyn E McFarlane, Taylor E Otto, Cynthia Terry, John C Gensel

Open access · greenAbstract read
In one paragraph

Article in Experimental neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Antioxidant Therapies in Traumatic Brain Injury.Antioxidants (Basel, Switzerland) · 2020
    Review
  12. Article
  13. Review
  14. Effects ofEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Michelle E SchoberDepartment of Pediatrics, Division of Critical Care University of Utah, Salt Lake City, UT 84132, United States. Electronic address: michelle.schober@hsc.utah.edu.
Daniela F RequenaDepartment of Pediatrics, Division of Critical Care University of Utah, Salt Lake City, UT 84132, United States.
T Charles CasperDepartment of Pediatrics, Division of Critical Care University of Utah, Salt Lake City, UT 84132, United States. Electronic address: Charlie.Casper@hsc.utah.edu.
Amy K VelhorstDepartment of Physiology and Spinal Cord and Brain Injury Research Center, University of Kentucky College of Medicine, Lexington, KY 40536, United States.
Alyssa LolofieDepartment of Pediatrics, Division of Critical Care University of Utah, Salt Lake City, UT 84132, United States. Electronic address: Alyssa.lolofie@hsc.utah.edu.
Katelyn E McFarlaneDepartment of Physiology and Spinal Cord and Brain Injury Research Center, University of Kentucky College of Medicine, Lexington, KY 40536, United States. Electronic address: katelynmcfarlane@uky.edu.
Taylor E OttoDepartment of Physiology and Spinal Cord and Brain Injury Research Center, University of Kentucky College of Medicine, Lexington, KY 40536, United States.
Cynthia TerryDepartment of Pediatrics, Division of Critical Care University of Utah, Salt Lake City, UT 84132, United States. Electronic address: cynthia.terry@hsc.utah.edu.
John C GenselDepartment of Physiology and Spinal Cord and Brain Injury Research Center, University of Kentucky College of Medicine, Lexington, KY 40536, United States. Electronic address: gensel.1@uky.edu.
University of Utah · USUniversity of Kentucky · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Univ of Utah Cell Sorter for Flow Cytometry CoreS10RR026802 · NCRR · UNIVERSITY OF UTAH · PI GREEN, WAYNE FRANCIS · 2010 to 2010
$500k
Mechanisms of Docosahexaenoic Acid Neuroprotection after Rat Pup TBIR21NS090098 · NINDS · UNIVERSITY OF UTAH · PI SCHOBER, MICHELLE ELENA · 2015 to 2016
$423k
NCI NIH HHS P30 CA042014NCRR NIH HHS S10 RR026802NINDS NIH HHS R21 NS090098
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is the leading cause of acquired neurologic disability in children, yet specific therapies to treat TBI are lacking. Therapies that decrease the inflammatory response and enhance a reparative immune action may decrease oxidative damage and improve outcomes after TBI. Docosahexaenoic acid (DHA) modulates the immune response to injury in many organs. DHA given in the diet before injury decreased rat pup cognitive impairment, oxidative stress and white matter injury in our developmental TBI model using controlled cortical impact (CCI). Little is known about DHA effects on neuroinflammation in the developing brain. Further, it is not known if DHA given after developmental TBI exerts neuroprotective effects. We hypothesized that acute DHA treatment would decrease oxidative stress and improve cognitive outcome, associated with decreased pro-inflammatory activation of microglia, the brain's resident macrophages.

methods17-day-old rat pups received intraperitoneal DHA or vehicle after CCI or SHAM surgery followed by DHA diet or continuation of REG diet to create DHACCI, REGCCI, SHAMDHA and SHAMREG groups. We measured brain nitrates/nitrites (NOx) at post injury day (PID) 1 to assess oxidative stress. We tested memory using Novel Object Recognition (NOR) at PID14. At PID 3 and 7, we measured reactivity of microglial activation markers Iba1, CD68 and CD206 and astrocyte marker GFAP in the injured cortex. At PID3, 7 and 30 we measured mRNA levels of inflammation-related genes and transcription factors in flow-sorted brain cells.

resultsDHA decreased oxidative stress at PID1 and pro-inflammatory microglial activation at PID3. CCI increased mRNA levels of two interferon regulatory family transcription factors, blunted by DHA, particularly in microglia-enriched cell populations at PID7. CCI increased mRNA levels of genes associated with "pro- " and "anti-" inflammatory activity at PID3, 7 and 30. Most notably within the microglia-enriched population, DHA blunted increased mRNA levels of pro-inflammatory genes at PID 3 and 7 and of anti-inflammatory genes at PID 30. Particularly in microglia, we observed parallel activation of pro-inflammatory and anti-inflammatory genes. DHA improved performance on NOR at PID14 after CCI.

conclusionsDHA decreased oxidative stress and histologic and mRNA markers of microglial pro-inflammatory activation in rat pup brain acutely after CCI associated with improved short term cognitive function. DHA administration after CCI has neuroprotective effects, which may result in part from modulation of microglial activation toward a less inflammatory profile in the first week after CCI. Future and ongoing studies will focus on phagocytic function and reactive oxygen species production in microglia and macrophages to test functional effects of DHA on neuroinflammation in our model. Given its favorable safety profile in children, DHA is a promising candidate therapy for pediatric TBI.

Indexed as

AnimalsAntioxidantsBrainBrain Injuries, TraumaticDocosahexaenoic AcidsInflammationMaleNeuroprotective AgentsOxidative StressRatsRats, Sprague-DawleyAntioxidantsDocosahexaenoic AcidsNeuroprotective AgentsControlled cortical impactDeveloping brainDocosahexaenoic acidNeuroinflammationRats

Identifiers

PMID31247195
PMCPMC6708465
OpenAlexW2953874040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.